Get to know our clinical trials
Phase I/II, open-label clinical trial of T3P-Y058-739, a genetically modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
THE PRIMARY OBJECTIVE OF THE TRIAL IS TO DETERMINE: THE BEST WAY TO SAFELY ADMINISTER T3P TO PATIENTS; THE SIDE EFFECTS OF T3P AND HOW THEY CAN BE MANAGED; AND WHETHER T3P CAN SHRINK OR CONTROL CANCERS.
Codirector
Immunology and Immunotherapy Department
Navarre headquarters
Technical Summary
- PHASE I/II, OPEN-LABEL STUDY OF T3P-Y058-739, A GENETICALLY MODIFIED STRAIN OF THE BACTERIUM YERSINIA ENTEROCOLITICA, IN PATIENTS WITH ADVANCED SOLID TUMORS.
- Code EudraCT: 2023-504199-19-00
- Protocol number: T3P1001
- Promoter: T3 Pharma
- Molecule/Drug: T3P
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.